Here we could show that tumor cells of PC besides being senescent also exhibit stem cell features. To investigate these surprising findings in more detail, we established a murine model based on tumor ...

Traditional immunotherapies mainly focus on αβ T cell-based strategies, which depend on MHC-mediated antigen recognition. However, this approach poses significant challenges in treating recurrent ...

Non-small cell lung cancer (NSCLC) is the most common form of lung cancer, accounting for 80 to 85% of all cases of lung cancer. There are different stages of NSCLC, ranging from 0 to 4; ...

To create one of the most advanced immunotherapies in cancer, CAR-T cell therapies, scientists engineer immune T cells to carry a synthetic protein on their surfaces. This protein, called the ...

Get Instant Summarized Text (Gist) Research has uncovered why tumor cells die differently after radiotherapy, revealing that DNA repair pathways dictate the mode of cell death. When homologous ...

Brain Tumor Organoids Accurately Model Patient Response to CAR T Cell Therapy Dec. 9, 2024 — Researchers used lab-grown organoids created from tumors of individuals with glioblastoma (GBM ...

Chimeric antigen receptor-T (CAR-T) cell therapy, initially successful in hematologic malignancies, presents a promising avenue for treating solid tumors, including CRC. This review explores the ...

to target a cell-surface receptor called DR5 (death receptor 5) that many tumor cells have. When activated, DR5 can trigger the death of these cells by a self-destruct process called apoptosis.

The TP53 gene is a gene that is mutated in many cancers. It is the most common gene mutation found in cancer cells. A tumor-suppressor gene, TP53 codes for a protein that inhibits the development and ...

Many cancer drugs work by inhibiting the activity of proteins — the molecules that do most of the work in the cell. But some misbehaving proteins that turn normal cells cancerous are difficult to ...